humans |
39 |
male |
24 |
aged |
23 |
female |
23 |
middle aged |
22 |
adult |
19 |
gastric cancer |
17 |
medical sciences |
17 |
helicobacter pylori |
14 |
aged, 80 and over |
13 |
stomach neoplasms - genetics - pathology |
12 |
prognosis |
11 |
treatment outcome |
11 |
gene expression regulation, neoplastic |
10 |
mutation |
10 |
prevalence |
10 |
proto-oncogene proteins - genetics |
10 |
transcription factors - genetics |
10 |
antigens, cd44 - genetics - metabolism |
9 |
gastric carcinoma |
9 |
immunoglobulin heavy chains - genetics |
9 |
immunohistochemistry |
9 |
lymphoma, follicular - genetics - pathology |
9 |
lymphoma, large b-cell, diffuse - genetics - pathology |
9 |
stomach neoplasms - genetics |
9 |
base sequence |
8 |
cadherins - blood |
8 |
dna mutational analysis |
8 |
drug therapy, combination |
8 |
enzyme inhibitors - therapeutic use |
8 |
gist |
8 |
promoter regions, genetic |
8 |
tumor markers, biological - blood |
8 |
adenocarcinoma - blood - diagnosis |
7 |
cell proliferation - drug effects |
7 |
diagnosis |
7 |
dna-binding proteins - genetics |
7 |
e-cadherin |
7 |
gastric adenocarcinoma |
7 |
hong kong |
7 |
lymphoma - epidemiology - genetics |
7 |
nicotine |
7 |
predictive value of tests |
7 |
prospective studies |
7 |
proto-oncogene proteins c-bcl-6 |
7 |
stomach neoplasms - blood - diagnosis |
7 |
stomach neoplasms - epidemiology - genetics |
7 |
translocation, genetic |
7 |
tumor marker |
7 |
adolescent |
6 |
anti-bacterial agents - pharmacology - therapeutic use |
6 |
anti-bacterial agents - therapeutic use |
6 |
anti-ulcer agents - therapeutic use |
6 |
breath tests |
6 |
clarithromycin - therapeutic use |
6 |
colon cancer |
6 |
gastroenterology |
6 |
helicobacter infections - complications |
6 |
helicobacter infections - drug therapy |
6 |
microsatellite repeats - genetics |
6 |
omeprazole - pharmacology - therapeutic use |
6 |
omeprazole - therapeutic use |
6 |
palliative care |
6 |
postoperative complications |
6 |
retrospective studies |
6 |
survival rate |
6 |
academic medical centers |
5 |
adc |
5 |
amoxicillin - pharmacology - therapeutic use |
5 |
anti-inflammatory agents, non-steroidal - adverse effects |
5 |
carcinoembryonic antigen |
5 |
cigarette smoke |
5 |
decorin |
5 |
diffusion magnetic resonance imaging |
5 |
dna methylation |
5 |
dna-binding proteins - biosynthesis - genetics |
5 |
double-blind method |
5 |
drug administration schedule |
5 |
emt |
5 |
fibrosis |
5 |
gene expression profiling |
5 |
h(+)-k(+)-exchanging atpase - antagonists & inhibitors |
5 |
helicobacter infections - drug therapy - metabolism |
5 |
hong kong - epidemiology |
5 |
hospital mortality |
5 |
immunoglobulins - chemistry |
5 |
inflammation |
5 |
li-cadherin |
5 |
lymphoma - genetics |
5 |
molecular sequence data |
5 |
morbidity |
5 |
neoplasm staging |
5 |
nicotine - pharmacology |
5 |
ofloxacin - pharmacology - therapeutic use |
5 |
oligonucleotide array sequence analysis |
5 |
pancreaticoduodenectomy - mortality - standards |
5 |
peptic ulcer - chemically induced - microbiology - prevention & control |
5 |
peritoneal dialysis |
5 |
peritonitis |
5 |
pet/ct |
5 |
protein transport |
5 |
recurrence |
5 |
recurrence - prevention & control |
5 |
referral and consultation |
5 |
risk factors |
5 |
rna, messenger - genetics |
5 |
rt-pcr |
5 |
sequence homology, nucleic acid |
5 |
stomach neoplasms - diagnosis - genetics - mortality |
5 |
stress |
5 |
suv |
5 |
telecommunication |
5 |
tumour marker |
5 |
undergraduate |
5 |
1-phosphatidylinositol 3-kinase - genetics |
4 |
2-pyridinylmethylsulfinylbenzimidazoles |
4 |
acp |
4 |
adenocarcinoma - diagnosis - genetics - mortality |
4 |
adenocarcinoma - etiology - genetics - metabolism |
4 |
adenocarcinoma - genetics |
4 |
adenocarcinoma - genetics - metabolism |
4 |
adenocarcinoma - metabolism - pathology |
4 |
adenocarcinoma - metabolism - physiopathology |
4 |
adrenaline |
4 |
adrenergic beta-antagonists - pharmacology |
4 |
airway obstruction - therapy |
4 |
algorithms |
4 |
amoxicillin - therapeutic use |
4 |
anti-infective agents - pharmacology - therapeutic use |
4 |
anti-ulcer agents - pharmacology - therapeutic use |
4 |
antibodies, bispecific |
4 |
antineoplastic agents - therapeutic use |
4 |
atenolol - pharmacology |
4 |
azacitidine - analogs & derivatives - therapeutic use |
4 |
bax |
4 |
bcl-2-associated x protein |
4 |
biliary tract neoplasms - complications - mortality |
4 |
biomarker |
4 |
biopsy - instrumentation - methods |
4 |
bismuth |
4 |
blotting, western |
4 |
breast neoplasms - blood - diagnosis - genetics - pathology |
4 |
butadienes - pharmacology |
4 |
cadherins |
4 |
cadherins - genetics - metabolism |
4 |
capd |
4 |
carbon isotopes - diagnostic use |
4 |
carcinoma - genetics - pathology - virology |
4 |
carcinoma, hepatocellular - mortality - surgery |
4 |
carcinoma, squamous cell - mortality - therapy |
4 |
cardia |
4 |
cardiopulmonary resuscitation |
4 |
cardiopulmonary resuscitation - adverse effects |
4 |
carrier proteins - genetics - metabolism |
4 |
ccl |
4 |
cdx2 |
4 |
cell line |
4 |
cell line, tumor |
4 |
cell survival - drug effects |
4 |
cell transformation, neoplastic - genetics |
4 |
cells, cultured |
4 |
chemokine (c-c motif) ligand |
4 |
chemokines, cc - genetics - immunology |
4 |
choledochostomy |
4 |
cholestasis - etiology - surgery |
4 |
cholestasis - mortality - surgery - therapy |
4 |
ci |
4 |
circulating microrna |
4 |
clarithromycin |
4 |
clarithromycin - pharmacology - therapeutic use |
4 |
collagen type i - genetics |
4 |
combined modality therapy |
4 |
complication |
4 |
confidence interval |
4 |
connective tissue growth factor - genetics - metabolism |
4 |
cox-2 |
4 |
cpg islands - genetics |
4 |
cpr |
4 |
ctgf/ccn2 |
4 |
culture media, conditioned |
4 |
cyclooxygenase 2 - biosynthesis |
4 |
cytokines - genetics - metabolism |
4 |
diagnostic marker |
4 |
dialysis solutions - toxicity |
4 |
disease progression |
4 |
dna methylation - genetics |
4 |
dna microarray |
4 |
dna modification methylases - antagonists & inhibitors |
4 |
dna primers |
4 |
dna, neoplasm - genetics |
4 |
dna-binding proteins - metabolism |
4 |
dose-response relationship, drug |
4 |
down-regulation |
4 |
down-regulation - genetics |
4 |
drainage |
4 |
drug resistance |
4 |
drug synergism |
4 |
drug therapy, combination - methods |
4 |
dyspepsia - pathology |
4 |
empirical first-line eradication |
4 |
endoscopy, digestive system - instrumentation |
4 |
endothelial cells - drug effects - metabolism - pathology |
4 |
enzyme induction - drug effects |
4 |
enzyme-linked immunosorbent assay |
4 |
ep4 |
4 |
epithelial cells - drug effects - metabolism - pathology |
4 |
epithelial cells - physiology |
4 |
epstein-barr virus |
4 |
equipment reuse |
4 |
esophageal neoplasms - mortality - therapy |
4 |
esophageal neoplasms - psychology - surgery |
4 |
esophagectomy |
4 |
exome |
4 |
extracellular signal-regulated map kinases - metabolism |
4 |
fibroblasts - drug effects - metabolism - pathology |
4 |
first aid - adverse effects |
4 |
follow-up studies |
4 |
gastric mucosa - physiology |
4 |
gastric rupture |
4 |
gastritis |
4 |
gene amplification |
4 |
gene expression - drug effects |
4 |
gene expression regulation, neoplastic - immunology |
4 |
gene silencing |
4 |
genes, tumor suppressor - genetics |
4 |
hazard ratio |
4 |
heimlich maneuver |
4 |
helicobacter |
4 |
helicobacter infections - drug therapy - pathology |
4 |
helicobacter pylori - drug effects |
4 |
helix-loop-helix motifs |
4 |
hepatectomy |
4 |
herpesviridae infections - complications |
4 |
herpesvirus 4, human - pathogenicity |
4 |
histone deacetylase inhibitors |
4 |
hmlh1 |
4 |
homeodomain proteins - genetics - metabolism |
4 |
hong kong chinese |
4 |
hr |
4 |
hydroxamic acids - therapeutic use |
4 |
id4 |
4 |
ihc |
4 |
immunoenzyme techniques |
4 |
inhibitor of differentiation proteins |
4 |
interleukin-6 - genetics |
4 |
intestinal metaplasia |
4 |
jak-stat |
4 |
leptin |
4 |
leptin - physiology |
4 |
leptin receptor |
4 |
levofloxacin |
4 |
liver neoplasms - mortality - surgery |
4 |
liver neoplasms - surgery - therapy |
4 |
lymph node metastasis |
4 |
lymphatic metastasis |
4 |
lymphatic metastasis - genetics |
4 |
macrophage migration-inhibitory factor |
4 |
macrophage migration-inhibitory factors - blood |
4 |
macrophages - physiology |
4 |
matrix metalloproteinase |
4 |
matrix metalloproteinase 9 - genetics |
4 |
medical education |
4 |
membrane proteins - biosynthesis |
4 |
membrane transport proteins |
4 |
membrane transport proteins - genetics |
4 |
mesothelial cell |
4 |
metaplasia - metabolism |
4 |
metronidazole - pharmacology - therapeutic use |
4 |
metronidazole - therapeutic use |
4 |
microarray |
4 |
micrornas - physiology |
4 |
microsatellite instability |
4 |
microsatellite repeats |
4 |
mir-92 |
4 |
mitogens - pharmacology |
4 |
mmp |
4 |
mucosal immunity |
4 |
neoplasm proteins - genetics - metabolism |
4 |
neoplasm recurrence, local - blood |
4 |
neoplasm staging - methods |
4 |
nf-kappa b - physiology |
4 |
nf-κb |
4 |
nitriles - pharmacology |
4 |
notch1 |
4 |
nuclear proteins - genetics |
4 |
ofloxacin - therapeutic use |
4 |
online synchronous education |
4 |
online teaching |
4 |
pancreatic neoplasms - complications |
4 |
parenteral nutrition |
4 |
peritoneal dialysis, continuous ambulatory - adverse effects |
4 |
peritoneum - cytology |
4 |
peritoneum - drug effects - metabolism - pathology |
4 |
phosphorylation - drug effects |
4 |
polymerase chain reaction |
4 |
postoperative complications - epidemiology - mortality |
4 |
precancerous conditions - metabolism |
4 |
preoperative care |
4 |
proliferation |
4 |
promoter methylation |
4 |
propanolamines - pharmacology |
4 |
proportional hazards models |
4 |
protein kinase c |
4 |
protein kinase c - metabolism |
4 |
protein kinase inhibitors - pharmacology |
4 |
protein transport - drug effects |
4 |
proto-oncogene proteins c-bcl-2 |
4 |
quality of life |
4 |
ranitidine - analogs & derivatives |
4 |
receptors, adrenergic, beta - drug effects - metabolism |
4 |
receptors, cell surface - biosynthesis |
4 |
receptors, leptin |
4 |
receptors, prostaglandin e, ep2 subtype - physiology |
4 |
receptors, prostaglandin e, ep4 subtype - physiology |
4 |
receptors, transforming growth factor beta - genetics |
4 |
respiratory diseases |
4 |
reverse transcriptase polymerase chain reaction - methods |
4 |
reverse-transcription polymerase chain reaction |
4 |
rna, messenger - genetics - metabolism |
4 |
signal transduction - drug effects |
4 |
specimen handling - instrumentation - methods - nursing |
4 |
ssc |
4 |
standard saline citrate |
4 |
statistics, nonparametric |
4 |
staurosporine - pharmacology |
4 |
stomach - pathology |
4 |
stomach neoplasms - blood - diagnosis - genetics - pathology |
4 |
stomach neoplasms - blood - diagnosis - mortality |
4 |
stomach neoplasms - blood - surgery |
4 |
stomach neoplasms - etiology - genetics - metabolism |
4 |
stomach neoplasms - genetics - metabolism |
4 |
stomach neoplasms - genetics - pathology - virology |
4 |
stomach neoplasms - metabolism - pathology |
4 |
stomach neoplasms - metabolism - physiopathology |
4 |
stomach neoplasms - pathology |
4 |
stomach neoplasms - psychology - surgery |
4 |
stomach rupture - etiology |
4 |
survival analysis |
4 |
t-lymphocytes - immunology |
4 |
tartrate-resistant acid phosphatase |
4 |
tgf-β |
4 |
transcription factor ap-1 - biosynthesis |
4 |
transcription factors - metabolism |
4 |
transforming growth factor beta - biosynthesis |
4 |
transforming growth factor beta - genetics - metabolism |
4 |
tumor markers, biological - analysis |
4 |
tumor markers, biological - genetics |
4 |
tumor markers, biological - genetics - metabolism |
4 |
tumor virus infections - complications |
4 |
tβrii |
4 |
undergraduate education |
4 |
up-regulation |
4 |
urea - analysis |
4 |
vascular endothelial growth factor a - genetics - metabolism |
4 |
vegf |
4 |
β-adrenergic receptor |
4 |
5-lox |
3 |
adenocarcinoma - complications - microbiology |
3 |
administration, oral |
3 |
analgesics, opioid - pharmacology |
3 |
anastomosis, surgical |
3 |
animals |
3 |
antacids - administration & dosage - therapeutic use |
3 |
anti-bacterial agents - administration & dosage - therapeutic use |
3 |
anti-infective agents - administration & dosage - adverse effects - pharmacology |
3 |
anti-inflammatory agents, non-steroidal - administration & dosage - adverse effects - therapeutic use |
3 |
anti-obesity agents - adverse effects - pharmacokinetics - pharmacology |
3 |
anti-ulcer agents - administration & dosage |
3 |
anti-ulcer agents - administration & dosage - therapeutic use |
3 |
antibodies, bacterial - blood |
3 |
apoptosis - drug effects |
3 |
arachidonate 5-lipoxygenase - metabolism |
3 |
asian continental ancestry group - ethnology |
3 |
aspirin - administration & dosage |
3 |
bacterial artificial chromosome |
3 |
bile - chemistry |
3 |
bile acids and salts - chemistry |
3 |
biliary obstruction |
3 |
biopsy |
3 |
blood vessels - drug effects |
3 |
c-myc |
3 |
cancer cell |
3 |
carcinogens - toxicity |
3 |
carcinoma |
3 |
carcinoma - genetics |
3 |
carcinoma - metabolism - virology |
3 |
carcinoma, hepatocellular |
3 |
carcinoma, hepatocellular - surgery |
3 |
carcinoma, squamous cell - genetics |
3 |
carcinoma, squamous cell - mortality - surgery |
3 |
celecoxib |
3 |
cell division - drug effects |
3 |
cell proliferation |
3 |
chi-square distribution |
3 |
cholangiocarcinoma |
3 |
cholesterol - metabolism |
3 |
chromosome aberrations |
3 |
chromosome deletion |
3 |
cirrhosis |
3 |
clarithromycin - administration & dosage - therapeutic use |
3 |
clinical trials as topic |
3 |
cohort studies |
3 |
cold temperature |
3 |
comparative genomic hybridization |
3 |
complementary dna |
3 |
cyclin d1 - genetics |
3 |
cyclooxygenase 2 inhibitors - adverse effects - therapeutic use |
3 |
cyclooxygenase-2 |
3 |
digestive system surgical procedures - methods |
3 |
distance learning |
3 |
dna, satellite - genetics |
3 |
drainage - methods |
3 |
duodenal ulcer - drug therapy - microbiology - pathology |
3 |
dyspepsia - chemically induced |
3 |
endoscopes - adverse effects |
3 |
endoscopy, digestive system - adverse effects |
3 |
energy intake |
3 |
enzyme inhibitors - adverse effects - pharmacokinetics - pharmacology |
3 |
enzyme-linked immunosorbent assay - methods - standards |
3 |
epithelial cells - cytology |
3 |
eradication |
3 |
esophageal neoplasms - genetics |
3 |
esophageal neoplasms - mortality - pathology - surgery |
3 |
esophageal neoplasms - mortality - surgery |
3 |
esophageal neoplasms - radiography - surgery |
3 |
esophageal neoplasms - surgery |
3 |
esophagectomy - adverse effects |
3 |
esophagectomy - methods |
3 |
european continental ancestry group - ethnology |
3 |
gallbladder - drug effects - physiology |
3 |
gastric mucosa - blood supply - drug effects - pathology |
3 |
gastric ulcer |
3 |
genes, ras |
3 |
head and neck neoplasms - metabolism - virology |
3 |
helicobacter infections - complications - microbiology |
3 |
helicobacter infections - diagnosis - ethnology |
3 |
helicobacter pylori - immunology |
3 |
helicobacter pylori - isolation and purification |
3 |
hepatectomy - methods |
3 |
hepatic resection |
3 |
hepatitis, chronic - pathology - surgery |
3 |
hepatolithiasis |
3 |
herpesvirus 4, human - isolation & purification |
3 |
hyperalimentation |
3 |
iatrogenic disease |
3 |
immunoglobulin g - blood |
3 |
in situ hybridization |
3 |
in situ hybridization, fluorescence - methods |
3 |
incidence |
3 |
interleukin-1beta - genetics |
3 |
intraoperative complications - etiology - prevention & control |
3 |
karyotyping |
3 |
lactones - adverse effects - pharmacokinetics - pharmacology |
3 |
lansoprazole |
3 |
lipase - antagonists & inhibitors |
3 |
lipids - analysis |
3 |
liver - pathology |
3 |
liver cirrhosis - pathology - surgery |
3 |
liver neoplasms - pathology - surgery |
3 |
liver neoplasms - surgery |
3 |
liver resection |
3 |
lung diseases - etiology |
3 |
lymphoma, b-cell, marginal zone - complications - microbiology |
3 |
mesoderm - cytology |
3 |
metronidazole - administration & dosage - therapeutic use |
3 |
midline incision |
3 |
mir-940 |
3 |
morphine |
3 |
morphine - pharmacology |
3 |
mortality |
3 |
mucus |
3 |
myeloperoxidase |
3 |
naloxone - pharmacology |
3 |
naproxen - administration & dosage - adverse effects - therapeutic use |
3 |
neoplasm proteins - genetics |
3 |
new south wales - epidemiology |
3 |
nitrosamines - toxicity |
3 |
nsaids |
3 |
nutritional support |
3 |
obesity - drug therapy - metabolism |
3 |
oesophagus |
3 |
omeprazole - administration & dosage |
3 |
omeprazole - administration & dosage - adverse effects - analogs & derivatives - pharmacology |
3 |
omeprazole - administration & dosage - analogs & derivatives - therapeutic use |
3 |
oncogene proteins - genetics |
3 |
online education |
3 |
organometallic compounds - therapeutic use |
3 |
ornithine decarboxylase |
3 |
p53 |
3 |
pbl |
3 |
peptic ulcer - chemically induced - epidemiology - prevention & control |
3 |
peptic ulcer hemorrhage - chemically induced |
3 |
peptic ulcer hemorrhage - etiology - prevention & control |
3 |
plasma |
3 |
platelet aggregation inhibitors - administration & dosage |
3 |
pleural drainage |
3 |
pneumoperitoneum - etiology - radiography |
3 |
postoperative care |
3 |
postoperative complications - epidemiology - prevention & control |
3 |
problem-based learning |
3 |
proto-oncogene proteins b-raf |
3 |
proton pumps - antagonists & inhibitors |
3 |
pylorus - surgery |
3 |
pyrazoles - adverse effects - therapeutic use |
3 |
radical gastrectomy surgery |
3 |
rats |
3 |
rats, sprague-dawley |
3 |
receptors, prostaglandin e, ep2 subtype - metabolism |
3 |
receptors, prostaglandin e, ep4 subtype - metabolism |
3 |
reconstructive surgical procedures |
3 |
sensitivity and specificity |
3 |
snail |
3 |
sphincterotomy, endoscopic - adverse effects - mortality - statistics & numerical data |
3 |
stomach - drug effects - pathology |
3 |
stomach - surgery |
3 |
stomach neoplasms - chemically induced - metabolism |
3 |
stomach neoplasms - complications - microbiology |
3 |
stomach neoplasms - enzymology - pathology |
3 |
stomach neoplasms - etiology |
3 |
stomach neoplasms - genetics - metabolism - pathology |
3 |
stomach neoplasms - metabolism - virology |
3 |
stomach neoplasms - surgery |
3 |
stomach ulcer - complications |
3 |
stomach ulcer - etiology - prevention & control |
3 |
stress, physiological - complications |
3 |
stromal tumour |
3 |
stump |
3 |
subcostal rooftop incision |
3 |
sulfonamides - adverse effects - therapeutic use |
3 |
surgical skills |
3 |
suture techniques |
3 |
syndrome |
3 |
ticlopidine - administration & dosage - analogs & derivatives |
3 |
time factors |
3 |
tumor suppressor protein p53 - metabolism |
3 |
ulcers |
3 |
weight loss |
3 |
wound healing - drug effects |
3 |
abdominal compartment syndrome |
2 |
abdominal pain - diagnosis - etiology |
2 |
acute disease |
2 |
adenocarcinoma - etiology - pathology |
2 |
adenocarcinoma - genetics - metabolism - pathology |
2 |
adrenergic receptors |
2 |
amplification |
2 |
angiogenesis |
2 |
anti-infective agents - therapeutic use |
2 |
apoptosis regulatory proteins - genetics |
2 |
appendicitis - complications - diagnosis |
2 |
array cgh |
2 |
assessment |
2 |
autonomic nerve tumor |
2 |
biocompatible materials |
2 |
cadherins - genetics |
2 |
cadherins - metabolism |
2 |
calcium-calmodulin-dependent protein kinases - genetics |
2 |
carcinoma, squamous cell - complications - diagnosis - surgery |
2 |
child |
2 |
child, preschool |
2 |
childhood dyspepsia |
2 |
cholangiocellular carcinoma |
2 |
choristoma - microbiology |
2 |
chromosomes, human, pair 19 |
2 |
citric acid - administration & dosage |
2 |
clinical application |
2 |
cluster analysis |
2 |
colon and rectal obstruction |
2 |
colorectal neoplasms - complications - mortality - radiography - surgery |
2 |
colostomy - instrumentation |
2 |
coronavirus disease 2019 |
2 |
cpg island methylator phenotype |
2 |
crohn's disease |
2 |
cyclin e - genetics - metabolism |
2 |
cytoskeletal proteins |
2 |
diagnosis, differential |
2 |
dna modification methylases |
2 |
dna repair enzymes |
2 |
dna, neoplasm - analysis |
2 |
drug combinations |
2 |
drug resistance, bacterial |
2 |
duodenal diseases - complications - diagnosis - surgery |
2 |
duodenal obstruction - complications - diagnosis |
2 |
duodenal ulcer |
2 |
dyspepsia - etiology |
2 |
dyspepsia - microbiology |
2 |
e-learning |
2 |
early gastric cancer |
2 |
education |
2 |
endoscopy |
2 |
endoscopy, gastrointestinal |
2 |
epstein-barr virus infections - etiology - pathology |
2 |
esophagus |
2 |
fatal outcome |
2 |
gastric mucosa |
2 |
gastric tumor |
2 |
gastric ulceration |
2 |
gastrointestinal neoplasms - genetics - pathology |
2 |
gene dosage |
2 |
gene expression |
2 |
general surgery |
2 |
genes, p16 |
2 |
genes, tumor suppressor |
2 |
graft vs host disease - complications - pathology |
2 |
group ii phospholipases a2 |
2 |
haemorrhage |
2 |
helicobacter infections - diagnosis |
2 |
helicobacter infections - epidemiology |
2 |
helicobacter pylori - isolation & purification |
2 |
hematopoietic stem cell transplantation - adverse effects |
2 |
herpesvirus 4, human - genetics - metabolism |
2 |
human |
2 |
il-2r |
2 |
interleukin-6 |
2 |
interleukin-6 - blood |
2 |
intestinal fistula - complications - diagnosis - surgery |
2 |
intestinal neoplasms - genetics |
2 |
intestinal obstruction - etiology - mortality - radiography - surgery |
2 |
intra-abdominal hypertension |
2 |
intrahepatic cholangiocarcinoma |
2 |
kidney calculi - complications - diagnosis - surgery |
2 |
kidney neoplasms - complications - diagnosis - surgery |
2 |
kidney pelvis - physiopathology - radiography |
2 |
kit |
2 |
laparoscopy |
2 |
laparotomy - methods |
2 |
meckel diverticulum - microbiology |
2 |
meckel's diverticulum |
2 |
metallic stents |
2 |
microarrays |
2 |
microrna |
2 |
mirna |
2 |
multiple myeloma - therapy |
2 |
mutations |
2 |
nachrs |
2 |
neoplasms, second primary |
2 |
nnk |
2 |
omeprazole - analogs & derivatives - therapeutic use |
2 |
oncogene proteins - genetics - metabolism |
2 |
oncogenes |
2 |
organometallic compounds |
2 |
patient compliance |
2 |
pdgfra |
2 |
peptic ulcer |
2 |
peptic ulcer - chemically induced - drug therapy |
2 |
phospholipases a - biosynthesis - genetics |
2 |
phosphoproteins - genetics |
2 |
promoter regions, genetic - genetics |
2 |
prosthesis implantation - instrumentation |
2 |
protein kinase c - genetics |
2 |
protein profiling |
2 |
proto-oncogene proteins c-kit |
2 |
receptor, ephb2 - biosynthesis - genetics |
2 |
receptor, platelet-derived growth factor alpha - genetics |
2 |
reverse transcriptase polymerase chain reaction |
2 |
risk assessment |
2 |
simulation |
2 |
skin lesion |
2 |
stomach diseases - microbiology |
2 |
stomach neoplasms - diagnosis - mortality - pathology |
2 |
stomach neoplasms - etiology - pathology |
2 |
stromal cells - pathology |
2 |
stromal tumor |
2 |
tablets |
2 |
tetracycline - therapeutic use |
2 |
tomography, x-ray computed |
2 |
tumor biomarkers |
2 |
tumor suppressor protein p14arf - genetics |
2 |
tumor suppressor proteins |
2 |
two-dimensional gel electrophoresis |
2 |
ulcerative colitis |
2 |
ultrasonography |
2 |
ultrastructural |
2 |
urea - administration & dosage - analysis |
2 |
urea breath test |
2 |
urinary fistula - complications - diagnosis - surgery |
2 |
adenocarcinoma - surgery |
1 |
adenomatous polyposis coli - epidemiology - genetics - therapy |
1 |
adenomyoma - ultrasonography |
1 |
aerosol |
1 |
antineoplastic combined chemotherapy protocols - therapeutic use |
1 |
asian continental ancestry group |
1 |
asian patients |
1 |
bile duct neoplasms - complications |
1 |
biliary stricture |
1 |
c-fos |
1 |
c-jun |
1 |
capsule endoscopy |
1 |
cautery |
1 |
chinese |
1 |
cholestasis - etiology - therapy |
1 |
choristoma |
1 |
circulating biomarker |
1 |
circulating dna |
1 |
circulating mirna |
1 |
colorectal neoplasms - epidemiology - genetics - therapy |
1 |
cryoglobulin |
1 |
cyclooxygenase |
1 |
cytology and histology |
1 |
demography |
1 |
dna markers |
1 |
early detection |
1 |
endoscopy - methods |
1 |
endosonography - methods |
1 |
epothilones - adverse effects - therapeutic use |
1 |
exosomal mirna |
1 |
extracellular signal-regulated protein kinases |
1 |
fluorouracil - administration and dosage |
1 |
gallbladder neoplasms - complications |
1 |
gastrectomy |
1 |
gastrectomy - psychology |
1 |
gastrointestinal bleeding |
1 |
gastrointestinal diseases - psychology |
1 |
haematogenous metastasis |
1 |
hbv |
1 |
health status |
1 |
helicobacter infections |
1 |
her2 |
1 |
human epidermal growth factor receptor 2 |
1 |
ixabepilone |
1 |
language |
1 |
liver - surgery |
1 |
malignancy |
1 |
metastasis |
1 |
mirna markers |
1 |
multiple organ resection |
1 |
neoplasms |
1 |
obscure origin |
1 |
oncology medical sciences |
1 |
pancreas |
1 |
pancreatectomy |
1 |
pancreatic pseudocyst |
1 |
peptic ulcer, surgery |
1 |
prostheses |
1 |
psychometrics |
1 |
quality control |
1 |
quality of life - psychology |
1 |
questionnaires |
1 |
radiology and nuclear medicine pharmacy and pharmacology biology |
1 |
registries |
1 |
reproducibility of results |
1 |
respirator |
1 |
second-line therapy |
1 |
self-report |
1 |
splenectomy |
1 |
stents |
1 |
stomach neoplasms |
1 |
stomach neoplasms - complications |
1 |
stomach neoplasms - drug therapy - mortality |
1 |
stomach neoplasms - ultrasonography |
1 |
structural aortic abnormality |
1 |
surgery |
1 |
toxicity |
1 |
translations |
1 |
tubulin modulators - therapeutic use |
1 |
tumor |
1 |